Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 3,253 matching trials from the live ClinicalTrials.gov search.

Filters: Not yet recruiting Clear all

Conditions: Pancreatic Surgery
Interventions: The Fresenius Kabi C.A.T.S®plus Continuous AutoTransfusion System; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: New York, New York

Conditions: Any Advanced Solid Tumors
Interventions: Sarilumab, ICI Therapy; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hypersensitivity Reactions, Allergic Contact Dermatitis
Interventions: Silk fibroin (SYLKE), 2-octyl cyanoacrylate mesh (Dermabond PRINEO); Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Nausea and Vomiting, Nausea, Vomiting
Interventions: Fosaprepitant for Injection, Metoclopramide Injection; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: HIV Prevention, Substance Use
Interventions: LYNX, Standard of Care; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 29 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Opioid Use Disorder
Interventions: Not listed
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Visual Acuity
Interventions: FaceScan; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Acute Ischemic Stroke
Interventions: AB126 Neural Exosomes Intravenous Injection, AB126 Placebo; Biological · Other
Lead sponsor: Aruna Bio, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Houston, Texas

Conditions: Plantar Fasciitis
Interventions: transdermal CBD cream (Tolcylen®, Marlinz Pharma), Matched Placebos; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Venous Thromboembolism (VTE)
Interventions: VTE Risk Assessment CDS Tool; Other
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 65,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Anxiety Disorders, OCD
Interventions: BraveBot, Self-Guided Exposure Therapy Homework; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 12 Years to 22 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 3
States / cities: Belmont, Massachusetts • Boston, Massachusetts • Cambridge, Massachusetts

Conditions: Down Syndrome Regression Disorder (DSRD), Down Syndrome (Trisomy 21), Neuroinflammatory / Neuropsychiatric Disorder
Interventions: Ublituximab; Drug
Lead sponsor: Jonathan Santoro; Other
Eligibility: 18 Years to 40 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Respiratory Distress Neonatal
Interventions: Adaptive Dynamic Inspiratory Nasal Apparatus, High flow Nasal Canula; Device
Lead sponsor: Loma Linda University; Other
Eligibility: 23 Weeks to 40 Weeks
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Glucose, High Blood
Interventions: Human Insulin, Finger-actuated, Metered Pump Sprayer; Biological · Device
Lead sponsor: Transdermal Delivery Solutions Corp; Industry
Eligibility: 25 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 1
States / cities: Palm Beach Gardens, Florida

Conditions: Amputation, Amputation, Traumatic, Amputation, Surgical, Upper Limb Amputation Above Elbow (Injury)
Interventions: eOPRA, OPRA, eOPRA with sensory feedback, eOPRA without sensory feedback; Device
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Remote vs. In-Person, Remote Visits, In-person Visits
Interventions: mobile health application (Moodivate); Behavioral
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years to 99 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Childhood Acute Lymphoblastic Leukemia, Childhood Lymphoblastic Lymphoma
Interventions: Non-Interventional Study; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: Up to 21 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cardiovascular Diseases, Insulin Sensitivity/Resistance, Metabolic Disease, Metabolism, Energy Expenditure, Obesity
Interventions: Vericiguat 10 MG, Placebo, Insulin Sensitivity Test, Resting Energy and Exercise Energy Expenditure Assessment, White Adipose Tissue Biopsy, MRI-PET Scan for Brown Adipose Tissue Volume Assessment; Drug · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 80 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Advanced Cancer, Cancer Pain, Chronic Pain
Interventions: Healing Gardens content development/refinement activities, Healing Gardens serious game; Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 2
States / cities: Boston, Massachusetts • Weymouth, Massachusetts

Conditions: Clear Cell Renal Cell Carcinoma (ccRCC)
Interventions: BMS-986527, Nivolumab, Cabozantinib; Drug
Lead sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 6
States / cities: New Haven, Connecticut • Basking Ridge, New Jersey • New York, New York + 3 more

Conditions: Healthy Volunteer, Obestity
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Alzheimer Disease, Aging
Interventions: Transcutaneous Auricular Vagus Nerve Stimulation (taVNS); Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Stanford, California

Conditions: Hearing Loss, Bilateral Sensorineural
Interventions: Cochlear implant; Procedure
Lead sponsor: University of Southern California; Other
Eligibility: 60 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Post-Bariatric Hypoglycemia
Interventions: Dietary Intervention, GLP-1 receptor agonist or Dual GIP/GLP-1 receptor agonist, Transoral Outlet Reduction (TORe); Behavioral · Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Palo Alto, California

Search by objective public record fields.

Salvaged Red Blood Cell Transfusion During Pancreatic Adenocarcinoma Operations

Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse Events

Evaluation of Hypersensitivity Reactions to Silk Fibroin Versus 2-octyl Cyanoacrylate Mesh in Shoulder Surgery

Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide

mHealth Service Linkage for Young Adults Impacted by the Criminal Legal System

Development of an Opioid Withdrawal Clinical Outcome Assessment

Evaluation of a Digital Visual Acuity Device vs. Standard Visual Acuity Measurements

A Phase 1b Study to Assess the Safety and Tolerability of AB126 Neural Exosomes in Patients With Moderate to Severe Acute Ischemic Stroke

A Double-Blinded Study on Rapid and Sustained Pain Relief Topical Cannabidiol for Plantar Fasciitis

The MInimizing RIsk of CLotting Events Trial

Digital Coach to Support Exposure Therapy Homework for Anxious Youth

An Open-Label Phase II Feasibility Study for the Use of Ublituximab in Adults With Down Syndrome Regression Disorder

ADINA vs. High Flow Nasal Cannula Comparison Study

Dose Response Study of Transdermal Human Insulin in Patients

Neuromusculoskeletal Interface for Bionic Arms

Remote vs. In-Person Study Evaluation (RISE) Trials: RISE Above Depression (Trial 2 of 3)

Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration

VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine Mono-Phosphate Signaling Pathway

Healing Gardens: Leveraging Serious Games to Deliver Accessible Pain-CBT and Pharmacologic Support for Patients With Advanced Cancer Managing Pain

A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)

Assessing the Impact of Perceptions of Unpredictability on Objective Measures of Food Consumption and Metabolism

Vagus Nerve Stimulation to Enhance Memory in Aging

Cochlear Implantation and Social Outcomes

Dietary, Medication, and Endoscopic Interventions for Post-Bariatric Hypoglycemia